The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

Clarity about the superiority of the two trastuzumab-containing ADCs in HER2 ... and Roche Products Ltd. Co-authors reported multiple relationships with industry.

and AZ/Daiichi Sankyo's Enhertu (trastuzumab deruxtecan). That is down to the company's ADC technology platform, which means that the cytotoxic payload that circulates systemically after ...

The addition of 64/67Cu-SAR-trastuzumab complements Clarity’s broader pipeline, which includes SAR-Bombesin, SARTATE, and SAR-bisPSMA. The company plans to conduct a Phase 1/2a theranostic study to ...

The FDA approved trastuzumab deruxtecan for a new breast cancer indication. The approval applies to patients with HER2-low or HER2-ultraow metastatic disease that progressed after endocrine therapy.

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

Puma Biotechnology will issue its 4Q and full year 2024 results on Feb. 27 and follow with a conference call at 1:30 p.m.

and co-authors performed a meta-analysis of mitochondria-related gene expression data in trastuzumab-treated cardiomyocytes. They analyzed 1,243 genes and observed 69 up-regulated genes after ...

The news: Clarity Pharmaceuticals shares tumbled after it announced a new treatment in its pipeline for breast cancer. The numbers: The clinical-stage radiopharmaceutical company’s shares dropped 5.36 ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).